12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RDEA3170: Interim Phase I data

Interim data from a Phase I trial in 6 healthy volunteers in a fasted state showed that a single 40 mg dose of RDEA3170 led to a 60% reduction in...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >